Role of endoscopy in predicting the disease course in inflammatory bowel disease

World Journal of Gastroenterology

Volumn 16, Issue 21, 2010, Pages 2626-2632

  Allez, Matthieu ^a   Lémann, Marc ^a  

^a INSERM   (France)

Author keywords

Colonoscopy; Crohn's disease; Inflammatory bowel disease; Medical therapy; Natural history; Outcome; Surgery; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BUDESONIDE; INFLIXIMAB; MESALAZINE; METHOTREXATE; PLACEBO; PREDNISOLONE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

CLINICAL TRIAL; COLON RESECTION; COLON SURGERY; COLON ULCER; COLONOSCOPY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; GASTROINTESTINAL ENDOSCOPY; HUMAN; PREDICTION; RECURRENCE RISK; REMISSION; REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 77953483107     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i21.2626     Document Type: Review

References (44)

1. Hanauer SB. Positioning biologic agents in the treatment of Crohn's disease. Infamm Bowel Dis 2009; 15: 1570-1582
2. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rut-geerts P. Infiximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395
3. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-667
4. Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S, D'Haens G. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastro-enterology 2010; 138: 463-468; quiz e10-e11
5. Fefferman DS, Farrell RJ. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin Gastroenterol Hepatol 2005; 3: 11-24
6. Hommes DW, van Deventer SJ. Endoscopy in inflammatory bowel diseases. Gastroenterology 2004; 126: 1561-1573
7. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeu-tiques des Affections Infammatoires du Tube Digestif (GE-TAID). Gut 1989; 30: 983-989
8. Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, Florent C, Bouvry M, Mary JY, Modigliani R. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Infamma-toires Digestives. Gut 1994; 35: 231-235
9. Daperno M, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, Mary JY, Colombel JF, Rutgeerts P. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004; 60: 505-512
10. Pineton de Chambrun G, Peyrin-Biroulet L, Lémann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 15-29
11. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gen-dre JP, Rene E. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflamma-toires Digestives. Gastroenterology 1990; 98: 811-818
12. Nahon S, Bouhnik Y, Lavergne-Slove A, Bitoun A, Panis Y, Valleur P, Vahedi K, Messing B, Matuchansky C, Rambaud JC. Colonoscopy accurately predicts the anatomical severity of colonic Crohn's disease attacks: correlation with fndings from colectomy specimens. Am J Gastroenterol 2002; 97: 3102-3107
13. Landi B, Anh TN, Cortot A, Soule JC, Rene E, Gendre JP, Bories P, See A, Metman EH, Florent C. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Infammatoires Digestives. Gastroenterology 1992; 102: 1647-1653
14. Allez M, Lemann M, Bonnet J, Cattan P, Jian R, Modigliani R. Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002; 97: 947-953
15. Rutgeerts P, Vermeire S, Van Assche G. What is the role of endoscopy in predicting Crohn's disease relapse or course? Infamm Bowel Dis 2008; 14 Suppl 2: S183-S184
16. Froslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-422
17. van Assche G, Vermeire S, Rutgeerts P. Mucosal healing and anti TNFs in IBD. Curr Drug Targets 2010; 11: 227-233
18. D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P. Endoscopic and histological healing with infiximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999; 116: 1029-1034
19. D'Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997; 112: 1475-1481
20. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histo-logic healing of Crohn's (ileo-) colitis with azathioprine. Gas-trointest Endosc 1999; 50: 667-671
21. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ. Tumor necrosis factor alpha antibody (infiximab) therapy profoundly down-regulates the infammation in Crohn's ileocolitis. Gastroenterology 1999; 116: 22-28
22. Mantzaris GJ, Christidou A, Sfakianakis M, Roussos A, Koilakou S, Petraki K, Polyzou P. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Infamm Bowel Dis 2009; 15: 375-382
23. Lémann M, Mary JY, Colombel JF, Duclos B, Soule JC, Lere-bours E, Modigliani R, Bouhnik Y. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005; 128: 1812-1818
24. Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB. Scheduled maintenance treatment with infiximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006; 63: 433-442; quiz 464
25. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Sch-reiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infiximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549
26. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P. Mucosal healing predicts long-term outcome of maintenance therapy with infiximab in Crohn's disease. Infamm Bowel Dis 2009; 15: 1295-1301
27. Louis E, Vernier-Massouille G, Grimaud JC, Bouhnik Y, La-harie D, Dupas JL, Pillant H, Picon L, Veyrac M, Flamant M, Savoye G, Jian R, De Vos M, Paintaud G, Piver E, Colombel JF, Mary JY, Lemann M. 961 infiximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort study. Gastroenterology 2009; 5 Suppl 1; A-146
28. Rutgeerts P, Van Assche G. What is the role of endoscopy in the postoperative management of Crohn's disease? Infamm Bowel Dis 2008; 14 Suppl 2: S179-S180
29. Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99: 956-963
30. Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, Hommes DW, Lochs H, Angelucci E, Cocco A, Vucelic B, Hildebrand H, Kolacek S, Riis L, Lukas M, de Franchis R, Hamilton M, Jantschek G, Michetti P, O'Morain C, Anwar MM, Freitas JL, Mouzas IA, Baert F, Mitchell R, Hawkey CJ. European evidence based consensus on the diagnosis and management of Crohn's disease: special situ ations. Gut 2006; 55 Suppl 1: i36-i58
31. Carbonnel F, Lavergne A, Lémann M, Bitoun A, Valleur P, Hautefeuille P, Galian A, Modigliani R, Rambaud JC. Colo-noscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 1994; 39: 1550-1557
32. Daperno M, Sostegni R, Scaglione N, Ercole E, Rigazio C, Rocca R, Pera A. Outcome of a conservative approach in severe ulcerative colitis. Dig Liver Dis 2004; 36: 21-28
33. Carbonnel F, Gargouri D, Lémann M, Beaugerie L, Cattan S, Cosnes J, Gendre JP. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000; 14: 273-279
34. Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Infamm Bowel Dis 2010; 16: 338-346
35. Hanauer SB, Sandborn WJ, Dallaire C, Archambault A, Yacyshyn B, Yeh C, Smith-Hall N. Delayed-release oral me-salamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can J Gastroenterol 2007; 21: 827-834
36. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith-Hall N, Ajayi F. De-layed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100: 2478-2485
37. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J 1954; 2: 375-378
38. Paoluzi OA, Pica R, Marcheggiano A, Crispino P, Iacopini F, Iannoni C, Rivera M, Paoluzi P. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid- resistant ulcerative colitis: results of an open-label study on effcacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 2002; 16: 1751-1759
39. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bi-anchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006; 55: 47-53
40. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lich-tenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476
41. Wright R, Truelove SR. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis 1966; 11: 847-857
42. Ferrante M, Vermeire S, Fidder H, Schnitzler F, Noman M, Van Assche G, De Hertogh G, Hoffman I, D'Hoore A, Van Steen K, Geboes K, Penninckx F, Rutgeerts P. Long-term outcome after infiximab for refractory ulcerative colitis. J Crohns colitis 2008; 2: 219-225
43. Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infiximab. Gastroenterology 2009; 137: 1250-1260; quiz 1520
44. Rimola J, Rodriguez S, García-Bosch O, Ordás I, Ayala E, Aceituno M, Pellisé M, Ayuso C, Ricart E, Donoso L, Panés J. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut 2009; 58: 1113-1120